Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

about

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

Item

http://www.wikidata.org/entity/Q42696471

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@en

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@nl

type

Item

label

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@en

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@nl

prefLabel

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@en

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@nl

P1476

Pharmacokinetics, Safety, and ...... fected With CCR5-Tropic HIV-1.

@en

P2093

Andrew Clark

http://www.w3.org/2001/XMLSchema#string

Annie Fang

http://www.w3.org/2001/XMLSchema#string

Carlo Giaquinto

http://www.w3.org/2001/XMLSchema#string

Elna van der Ryst

http://www.w3.org/2001/XMLSchema#string

Ismail Haroon Mitha

http://www.w3.org/2001/XMLSchema#string

Jan Fourie

http://www.w3.org/2001/XMLSchema#string

Jayvant Heera

http://www.w3.org/2001/XMLSchema#string

Kulkanya Chokephaibulkit

http://www.w3.org/2001/XMLSchema#string

Lynn McFadyen

http://www.w3.org/2001/XMLSchema#string

Manoli Vourvahis

http://www.w3.org/2001/XMLSchema#string

P2860

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Maraviroc for previously treated patients with R5 HIV-1 infection

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.

P304

459-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0000000000001808

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Charles Craig

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29023357

http://www.w3.org/2001/XMLSchema#string

P932

5916460

http://www.w3.org/2001/XMLSchema#string